• InvestorsInvestors
  • PatientsPatients
  • PressPress
  • Chercher dans le siteChercher dans le site

Select your language

  • FR
Alzprotect Alzprotect
  • Company
    • About the Company
    • Team
    • Partners
    • Careers
  • Expertise
    • Therapeutic Strategy
    • Research & Development
    • Publication
  • Pipeline
  • News
  • Contact

[EN] Secondary Menu

  • InvestorsInvestors
  • PatientsPatients
  • PressPress
  • Chercher dans le siteChercher dans le site

Select your language

  • FR

[ALL] Réseaux sociaux

News

Laboeatory

Alzprotect Establishes US Subsidiary

Lille (France), April 8th, 2021 – Alzprotect , a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today today hat it has established its US based subsidiary, Alzprotect US Inc . in Boston, Massachusetts, in line with its international development strategy. This new subsidiary of Alzprotect is situated in Boston. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technologi...

Read more …

Alzprotect to present at the 14th Annual European Life Sciences CEO Forum

Lille (France), March 7th, 2021 – Alzprotect , a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases is pleased to announce the company will present virtually at the 14th Annual European Life Sciences CEO Forum that will take place from the 10th to the 12th of March 2021, aspart of the Digital Sachs Spring Life Sciences Week. Philippe Verwaerde, Chief Executive Officer of Alzprotect will provide an overview of the development program of the company’s drug Ez...

Read more …

Alzprotect strengthens its Intellectual Property Portfolio for its First-in-Class Clinical Stage Drug Ezeprogind

Lille (France), November 23rd, 2020 – Alzprotect , a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office (USPTO) has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind (AZP2006) in the treatment of tauopathies. This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,5...

Read more …

Alzprotect forges ahead with first patients enrolled in Phase 2a study in Progressive Supranuclear Palsy (PSP)

Read more …

Alzprotect announces the WHO approval of generic name Ezeprogind for the « first-in-Class » AZP2006 clinical stage drug

Read more …

Brand identity: Alzprotect changes its signature

Read more …

Interview Biotech Finances

Interview Biotech Finances 25/06/2020

Read more …

Alzprotect obtains authorization to start a Phase 2a clinical trial in PSP

Read more …

Page 2 of 2

  • 1
  • 2
  • Alzprotect
  • Expertise
  • AZP2006
  • News
  • Investisseurs
  • Patients
  • Press

Alzprotect

85 Rue Nelson Mandela
59120 Loos
France
Tel. +33 972 649 757

Contact

  • Conditions générales d'utilisation
  • Confidentialité

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Ok Decline
More information